RUO onlyCognitive

Adamax

N-Acetyl Semax Amidate / Enhanced Semax / Semax analog

A modified version of Semax — N-acetylated and amidated — designed to improve enzymatic stability and potentially increase potency compared to standard Semax. Carries the same cognitive enhancement and neuroprotective research interest as Semax but with significantly less published research on the specific modification. Often described as a next-generation Semax.

Evidence

Preclinical only

Routes

nasal, injectable

Available since

Modified Semax analog available through RUO vendors.

Mechanism of action

Same base mechanism as Semax — BDNF and NGF elevation, cerebral blood flow improvement, ACTH analog activity. The N-acetyl amidate modification aims to slow enzymatic degradation, potentially allowing lower doses to produce equivalent or greater effects compared to standard Semax. The chemistry rationale is sound. Published validation in humans is absent.

Effects in the body

Adamax is to Semax what Adalank is to Selank — a chemically modified version of an established research peptide with theoretically improved pharmacokinetics but significantly less independent research validation. If Semax is your primary research interest, the Semax profile represents the stronger evidence base including 40+ years of Russian clinical use and the July 2026 PCAC favorable recommendation.

Pros & cons (from the literature)

Pros

Same mechanistic base as Semax — BDNF elevation, neuroprotection, cognitive enhancement
N-acetyl amidate modification may extend duration and reduce required dose
Intranasal administration available
Based on one of the best-evidenced cognitive peptides available

Cautions

Evidence tier 1 — minimal published research on Adamax specifically
All advantages over Semax are theoretical based on chemistry not human trials
No human clinical data on Adamax specifically
Standard Semax has the stronger evidence base and PCAC favorable recommendation — Adamax does not inherit that regulatory status

Protocol summary (from published research)

Intranasal administration most common — similar to Semax protocol. No established independent research protocol for Adamax specifically.

Dosing ranges reproduced from published research literature. Not a prescription, not medical advice.

FDA & regulatory status

Research Use Only. Not FDA approved. A modified version of Semax. Note: the PCAC favorable recommendation for Semax (July 2026) applies to Semax specifically — not to modified analogs like Adamax, which would require separate regulatory review.

Evidence base

No published peer-reviewed research on Adamax specifically. Evidence inherited conceptually from Semax parent compound. PCAC July 2026 recommendation applies to Semax only, not Adamax.

Primary research sources

Peer-reviewed literature referenced throughout this profile is drawn from PubMed, Cell Metabolism, and clinical trial registries cited in the evidence base above.

Important. ThePeptide.expert summarizes published research. We are not a pharmacy, do not prescribe, and make no therapeutic claims. Regulatory status varies by jurisdiction.